西维莱斯塔特通过激活PI3K/AKT/mTOR信号通路来改善败血症引起的心肌功能障碍
Hongyu Geng1, Hongbo Zhang2, Lianfang Cheng1
1Department of Intensive Care Unit, Baoding First Central Hospital, Baoding, China.
International immunopharmacology
|January 4, 2024
概括
作为中性粒细胞弹性酶抑制剂,西维莱斯塔特通过激活PI3K/AKT/mTOR通路,减少炎症和心肌细胞亡,保护免受败血症引起的心肌功能障碍.
科学领域:
- 心脏病学 心脏病学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 像西维莱斯塔特这样的中性粒细胞弹性酶抑制剂显示出心脏保护作用.
- 在心肌功能障碍中西维莱斯塔特的保护作用背后的精确分子机制尚未完全理解.
研究的目的:
- 为了研究sivelestat在败血症诱导的心肌功能障碍 (SIMD) 的分子机制.
主要方法:
- 在体外研究中使用脂多糖 (LPS) 刺激的H9c2细胞.
- 在体内研究涉及败血性大鼠.
- 评估细胞活力,细胞亡,炎症标志物 (TNF-α,IL-1β),心脏功能以及PI3K/AKT/mTOR通路.
主要成果:
- 西维莱斯塔改善了H9c2细胞活力,并减少了细胞亡.
- 在体内,sivelestat提高了生存率,降低了心脏损伤标志物,改善了心脏功能.
- 西维莱沙特调节了与亡相关的蛋白质 (Bcl-2,Bax,caspase-3) 并激活了PI3K/AKT/mTOR通路.
- 抑制PI3K可以逆转sivelestat的保护作用.
结论:
- 西维莱斯塔特对SIMD有保护作用.
- 这种保护是通过激活PI3K/AKT/mTOR信号通路来实现的.
相关概念视频
01:22PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K
01:20The JAK-STAT Signaling Pathway
8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.9K